| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
|
Lancet
|
2012
|
8.00
|
|
2
|
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
|
Lancet
|
2012
|
5.62
|
|
3
|
Combination chemotherapy in advanced adrenocortical carcinoma.
|
N Engl J Med
|
2012
|
2.82
|
|
4
|
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
|
J Clin Oncol
|
2010
|
2.61
|
|
5
|
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
|
Eur J Cancer
|
2011
|
2.23
|
|
6
|
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
|
J Clin Oncol
|
2012
|
2.02
|
|
7
|
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
Eur J Endocrinol
|
2009
|
1.78
|
|
8
|
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
|
J Clin Endocrinol Metab
|
2010
|
1.72
|
|
9
|
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
|
Clin Cancer Res
|
2008
|
1.60
|
|
10
|
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
|
J Clin Oncol
|
2009
|
1.60
|
|
11
|
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
|
Clin Cancer Res
|
2010
|
1.57
|
|
12
|
Clinical pharmacokinetics of tyrosine kinase inhibitors.
|
Cancer Treat Rev
|
2009
|
1.57
|
|
13
|
Outcome of advanced, unresectable conventional central chondrosarcoma.
|
Cancer
|
2014
|
1.51
|
|
14
|
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
|
Int J Cancer
|
2004
|
1.49
|
|
15
|
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
|
J Clin Oncol
|
2010
|
1.48
|
|
16
|
The clinical approach toward giant cell tumor of bone.
|
Oncologist
|
2014
|
1.46
|
|
17
|
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.
|
Eur Radiol
|
2009
|
1.44
|
|
18
|
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases.
|
J Thorac Oncol
|
2014
|
1.42
|
|
19
|
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
|
Cancer
|
2011
|
1.41
|
|
20
|
Translating pharmacogenomics: challenges on the road to the clinic.
|
PLoS Med
|
2007
|
1.39
|
|
21
|
Factors affecting cytochrome P-450 3A activity in cancer patients.
|
Clin Cancer Res
|
2004
|
1.36
|
|
22
|
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
|
Clin Cancer Res
|
2005
|
1.33
|
|
23
|
Prognostic factors in pulmonary metastasized high-grade osteosarcoma.
|
Pediatr Blood Cancer
|
2010
|
1.27
|
|
24
|
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
|
J Clin Oncol
|
2009
|
1.26
|
|
25
|
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
|
Clin Cancer Res
|
2011
|
1.24
|
|
26
|
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
|
Anticancer Drugs
|
2014
|
1.24
|
|
27
|
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
|
Mol Immunol
|
2008
|
1.23
|
|
28
|
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.
|
Oncologist
|
2011
|
1.22
|
|
29
|
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.
|
J Clin Oncol
|
2013
|
1.21
|
|
30
|
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
|
Eur J Cancer
|
2010
|
1.17
|
|
31
|
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
|
Cancer Biol Ther
|
2005
|
1.15
|
|
32
|
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.
|
Clin Cancer Res
|
2009
|
1.14
|
|
33
|
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
|
Clin Pharmacol Ther
|
2004
|
1.13
|
|
34
|
Epidemiology of Norwalk-like virus infections in cattle in The Netherlands.
|
Vet Microbiol
|
2003
|
1.13
|
|
35
|
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
|
Oncologist
|
2011
|
1.11
|
|
36
|
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
|
Clin Cancer Res
|
2011
|
1.07
|
|
37
|
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
|
Ann Surg Oncol
|
2006
|
1.07
|
|
38
|
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
|
Eur J Cancer
|
2011
|
1.06
|
|
39
|
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
|
Int J Cancer
|
2010
|
1.06
|
|
40
|
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
|
Cancer Chemother Pharmacol
|
2008
|
1.05
|
|
41
|
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
|
Cancer Chemother Pharmacol
|
2014
|
1.02
|
|
42
|
Tales of how great drugs were brought down by a flawed rationale--letter.
|
Clin Cancer Res
|
2013
|
1.02
|
|
43
|
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.
|
J Cutan Pathol
|
2008
|
1.02
|
|
44
|
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
|
Cancer Treat Rev
|
2008
|
1.01
|
|
45
|
Liposomal drug formulations in cancer therapy: 15 years along the road.
|
Drug Discov Today
|
2011
|
1.01
|
|
46
|
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.
|
Cancer Immunol Immunother
|
2011
|
0.99
|
|
47
|
Mammalian target of rapamycin inhibitor-associated stomatitis.
|
Future Oncol
|
2013
|
0.98
|
|
48
|
Pharmacogenetics of EGFR and VEGF inhibition.
|
Drug Discov Today
|
2007
|
0.97
|
|
49
|
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study.
|
Sarcoma
|
2012
|
0.95
|
|
50
|
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
|
World J Surg Oncol
|
2012
|
0.95
|
|
51
|
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.93
|
|
52
|
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
|
J Bone Miner Res
|
2005
|
0.92
|
|
53
|
Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events.
|
Support Care Cancer
|
2013
|
0.92
|
|
54
|
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.
|
Hematol Oncol Clin North Am
|
2013
|
0.91
|
|
55
|
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
|
Eur J Endocrinol
|
2011
|
0.90
|
|
56
|
A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2013
|
0.90
|
|
57
|
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
|
Cancer
|
2015
|
0.90
|
|
58
|
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
|
Clin Cancer Res
|
2007
|
0.89
|
|
59
|
Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
|
Clin Cancer Res
|
2013
|
0.89
|
|
60
|
Marginal increase of sunitinib exposure by grapefruit juice.
|
Cancer Chemother Pharmacol
|
2010
|
0.89
|
|
61
|
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle.
|
Hepatology
|
2005
|
0.88
|
|
62
|
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
|
Int J Cancer
|
2012
|
0.88
|
|
63
|
Osteosarcoma: evolution of treatment paradigms.
|
Sarcoma
|
2013
|
0.88
|
|
64
|
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
|
Clin Cancer Res
|
2005
|
0.88
|
|
65
|
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
|
Cancer Chemother Pharmacol
|
2014
|
0.87
|
|
66
|
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
|
Cancer Chemother Pharmacol
|
2008
|
0.87
|
|
67
|
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
|
Eur J Cancer
|
2008
|
0.87
|
|
68
|
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
|
Int J Cancer
|
2014
|
0.87
|
|
69
|
Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.
|
Pharmacogenomics
|
2013
|
0.86
|
|
70
|
Therapeutic modulation of k-ras signaling in colorectal cancer.
|
Drug Discov Today
|
2010
|
0.85
|
|
71
|
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
|
J Clin Oncol
|
2009
|
0.85
|
|
72
|
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics.
|
Int J Clin Pharm
|
2011
|
0.85
|
|
73
|
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.
|
J Surg Oncol
|
2012
|
0.85
|
|
74
|
Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup.
|
Virchows Arch
|
2012
|
0.84
|
|
75
|
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.
|
Clin Sarcoma Res
|
2011
|
0.84
|
|
76
|
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
|
Eur J Cancer
|
2010
|
0.84
|
|
77
|
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
|
Breast Cancer Res Treat
|
2014
|
0.84
|
|
78
|
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
|
Acta Oncol
|
2015
|
0.84
|
|
79
|
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
|
BMC Cancer
|
2014
|
0.84
|
|
80
|
Phenotyping drug disposition in oncology.
|
Cancer Treat Rev
|
2012
|
0.83
|
|
81
|
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
|
Ther Drug Monit
|
2015
|
0.82
|
|
82
|
Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
|
Ann Surg Oncol
|
2008
|
0.82
|
|
83
|
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
|
Anticancer Drugs
|
2003
|
0.82
|
|
84
|
Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
|
Pharmacogenet Genomics
|
2016
|
0.81
|
|
85
|
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
|
Invest New Drugs
|
2010
|
0.81
|
|
86
|
Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.
|
Eur J Oncol Nurs
|
2013
|
0.81
|
|
87
|
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
|
Oncology
|
2016
|
0.80
|
|
88
|
New systemic therapy options for advanced sarcomas.
|
Curr Treat Options Oncol
|
2012
|
0.80
|
|
89
|
Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.
|
Acta Orthop
|
2015
|
0.80
|
|
90
|
Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
|
Clin Genitourin Cancer
|
2013
|
0.80
|
|
91
|
Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
|
Eur J Endocrinol
|
2013
|
0.80
|
|
92
|
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
|
Pharmacogenet Genomics
|
2013
|
0.79
|
|
93
|
Diflomotecan, a promising homocamptothecin for cancer therapy.
|
Expert Opin Investig Drugs
|
2009
|
0.78
|
|
94
|
Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer.
|
Int J Gynecol Cancer
|
2012
|
0.78
|
|
95
|
Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.
|
Expert Opin Investig Drugs
|
2013
|
0.78
|
|
96
|
Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients.
|
Cancer Immunol Immunother
|
2012
|
0.78
|
|
97
|
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
|
Clin Cancer Res
|
2008
|
0.78
|
|
98
|
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
|
Breast Cancer Res Treat
|
2013
|
0.78
|
|
99
|
Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia.
|
Jpn J Clin Oncol
|
2011
|
0.78
|
|
100
|
Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
|
Ther Drug Monit
|
2015
|
0.77
|
|
101
|
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2002
|
0.77
|
|
102
|
Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle.
|
Pharmacogenomics
|
2010
|
0.77
|
|
103
|
Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
|
Pediatr Blood Cancer
|
2014
|
0.77
|
|
104
|
Pharmacogenetics in chemotherapy of colorectal cancer.
|
Best Pract Res Clin Gastroenterol
|
2009
|
0.77
|
|
105
|
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
|
Curr Opin Oncol
|
2016
|
0.77
|
|
106
|
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.
|
Pharmacogenet Genomics
|
2017
|
0.77
|
|
107
|
Tissue factor associates with survival and regulates tumour progression in osteosarcoma.
|
Thromb Haemost
|
2016
|
0.76
|
|
108
|
Osteosarcoma: lessons learned and future avenues.
|
Sarcoma
|
2013
|
0.76
|
|
109
|
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
|
Invest New Drugs
|
2009
|
0.76
|
|
110
|
Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians.
|
Int J Biol Markers
|
2012
|
0.76
|
|
111
|
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
|
Curr Opin Mol Ther
|
2010
|
0.76
|
|
112
|
Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients.
|
Anticancer Drugs
|
2015
|
0.76
|
|
113
|
False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature.
|
Oncologist
|
2008
|
0.76
|
|
114
|
Paratesticular desmoplastic small round cell tumour: an unusual tumour with an unusual fusion; cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH.
|
Clin Sarcoma Res
|
2012
|
0.75
|
|
115
|
SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
|
Clin Cancer Res
|
2011
|
0.75
|
|
116
|
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.
|
Invest New Drugs
|
2011
|
0.75
|
|
117
|
Emphasizing the value of phenotyping in patients receiving tamoxifen.
|
J Clin Oncol
|
2011
|
0.75
|
|
118
|
Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
|
Clin Orthop Relat Res
|
2019
|
0.75
|
|
119
|
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
120
|
Is rectal administration an alternative route for imatinib?
|
Cancer Chemother Pharmacol
|
2007
|
0.75
|
|
121
|
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
|
Jpn J Clin Oncol
|
2011
|
0.75
|
|
122
|
In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.
|
J Surg Res
|
2009
|
0.75
|
|
123
|
Current clinical trials for advanced osteosarcoma and soft tissue sarcoma.
|
Curr Opin Oncol
|
2014
|
0.75
|
|
124
|
Breath tests to phenotype drug disposition in oncology.
|
Clin Pharmacokinet
|
2013
|
0.75
|
|
125
|
Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
|
Am J Surg Pathol
|
2015
|
0.75
|
|
126
|
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
|
Pharmacogenet Genomics
|
2017
|
0.75
|